A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Takamaro Fukuoka Named as New Health Minister
October 1, 2024
-
REGULATORY Japan Compiles First Biosimilar Roadmap
October 1, 2024
-
ACADEMIA Pharmacies, Hospitals Scrambling to Address New LLP Coverage Rule, Concerns Swirl Around Misuse
October 1, 2024
-
REGULATORY Ishiba Elected as New LDP Leader, Hopes Are High for Medical and Pharma Policies
September 30, 2024
-
REGULATORY MHLW to Publish Info Necessary for Driving Biosimilar Switches in FY2025
September 27, 2024
-
REGULATORY Kisunla Subject to Prior Pricing Review as It Follows Leqembi’s Footsteps
September 26, 2024
-
REGULATORY Japan Approves Lilly’s Kisunla, Eisai’s ALS Med, Gilead’s Trodelvy, and Lots More
September 25, 2024
-
BUSINESS NHI-Market Price Gap on Narrowing Trend, but Results Remain Unpredictable
September 24, 2024
-
REGULATORY More Pregnant Cases Reported for COVID Meds, Panel Urges Greater Caution
September 24, 2024
-
BUSINESS Tsumura to Cover Return Costs for China Staff after Shenzhen Stabbing
September 24, 2024
-
REGULATORY MHLW to Update Decade-Old Generic Roadmap, Add Blueprint for Biosimilars
September 20, 2024
-
BUSINESS Asahi Kasei Pivots toward Drug Business in Healthcare to Drive Growth
September 19, 2024
-
BUSINESS UCB CEO Hails Positive Change in Japan’s Pharma Policy
September 19, 2024
-
BUSINESS GSK’s Multiple Myeloma Drug Blenrep Filed in Japan
September 18, 2024
-
REGULATORY 9 LDP Leader Candidates Showcase Pharma Agendas in Campaign
September 17, 2024
-
BUSINESS Eisai Set on Streamlining Operations to Drive Drug Innovation: COO
September 13, 2024
-
ORGANIZATION Pharma Industry Prepares List of 68 Lawmakers to Support in Likely Snap Poll
September 12, 2024
-
REGULATORY Mounjaro to Keep Price after CEA as Lilly’s Appeal for Raise Nixed
September 12, 2024
-
REGULATORY AMED Research Exploring Low-Cost Method to Analyze Nitrosamine Impurities
September 11, 2024
-
COMMENTARY LLP Info Might Become Inaccessible If New Coverage Rule Speeds Up Exit
September 10, 2024
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…